News

Keros Therapeutics: Interesting Early Data From A Promising Molecule (Downgrade) (KROS)

3 Mins read

In April, I covered Keros Therapeutics, Inc. (NASDAQ:KROS), and found it interesting. Keros had three published datasets from three clinical-stage programs. The stock had a short rally after my coverage, then went down, took another small leap, and then went down

Response summary

RP2D Patients

All evaluable patients

HTB evaluable patients

Overall Erythroid Response (HI-E or TI) n (%)

19/37 (51.4)

11/22 (50)

IWG 2006 HI-E, n (%)

19/37 (51.4)

11/22 (50)

TI ≥8 weeks, n (%)

11/26 (42.3)

9/22 (40.9)

RS+, n (%)

8/19 (42.1)

6/17 (35.3)

Non-RS, n (%)

3/7 (42.9)

3/5 (60)

Read the full article here

Related posts
News

Palantir: Building A Monopoly With Powerful Data Flywheel (NASDAQ:PLTR)

1 Mins read
This article was written by Follow “AWS Certified AI Practitioner Early Adopter”I am a DevOps Engineer for a major, wholly owned subsidiary…
News

Super Micro Computer: The Music’s Still Playing - But I’m Already Out (NASDAQ:SMCI)

1 Mins read
This article was written by Follow I’m passionate about finance and investing, focusing on business analysis, fundamental analysis, valuation, and long-term growth,…
News

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

1 Mins read
Talphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Raffi Asadorian – CFOVincent Angotti –…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *